Hydroxyethyl salicylate 6% / Methyl nicotinate 1.6% spray
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Hydroxyethyl salicylate + Methyl nicotinate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Ralgex brand family (generic: Hydroxyethyl salicylate + Methyl nicotinate)
MHRA licensed products
View all licensed products for Hydroxyethyl salicylate + Methyl nicotinate on the MHRA register
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · 1934–2026
Showing the 50 most relevant studies, sorted by most relevant.
María Rosa Rossetti, Nicolás Kuzmanich, Martín Videla, et al.
Entomologia Generalis, 2025
Denise Tieman, Michelle Zeigler, Eric Schmelz, et al.
The Plant Journal, 2010
2020
2020
Sun-Hwa Yeon, Ki-Sub Kim, Sukjeong Choi, et al.
Electrochimica Acta, 2005
Kai Ament, Vladimir Krasikov, Silke Allmann, et al.
The Plant Journal, 2010
Yi-Xia Wu, Ming-Xiu Liu, Wan-Ting Huang, et al.
Entomologia Generalis, 2024
I. Made Deago Nugra Visesa, Aditya Luthfi Trianjani, Annas Wiguno, et al.
E3S Web of Conferences, 2024
Gandapura oil, also called wintergreen oil in international trade, is evaluated based on the purity of its methyl salicylate content. Gandapura oil has several impurities including mainly ethyl salicylate and α-pinene, which can lower its quality and price. Indonesian local farmer’s gandapura oil has a low methyl salicylate content of only 82.23%, and appears in a dark red colour instead of clear. The low grade product may have been caused by thermal degradation of compounds within gandapura oil by constant heating during atmospheric distillation at temperature above its thermal threshold. The determination of their vapor-liquid equilibrium data can provide basic data for the separation and purification of methyl salicylate towards its two main impurities in gandapura oil. The vacuum pressure condition was selected to lower the distillation temperature, aiming to reduce the chance of thermal decomposition. The vapor-liquid equilibrium under isobaric conditions in the binary systems of methyl salicylate + ethyl salicylate and methyl salicylate + α-Pinene at 20.0 and 50.0 kPa were measured experimentally using modified Glass Othmer-Still. Gas Chromatography (GC) was utilized to analyze the composition of both the liquid and vapor phases in the samples. The thermodynamic consistency of experimental data was confirmed through the L-W Wisniak method. The experimental results were successfully correlated with Wilson, NRTL, and UNIQUAC models. The average absolute deviations of temperature (AAD T) and vapor phase composition (AAD y) between experimental data and models are less than 0.8058 and 0.0196, respectively for all systems. In terms of quality, all samples collected post-experiment maintained a clear color, suggesting that vacuum pressure distillation effectively prevents the thermal decomposition of compounds in gandapura oil.
Abstract licence: CC BY 4.0
Official Methods of Analysis of AOAC INTERNATIONAL, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.